William Gehin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
William Gehin has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Valérie Bernier-Chastagner
Department of Radiation Therapy, Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France
4 shared publications- Marie Bruand
Institut de Cancérologie de Lorraine, Department of Radiation Oncology, Vandœuvre-lès-Nancy, France
3 shared publications Nicolas Martz
3 shared publications- Aurélien Lambert
Medical Oncology Department, Institut de cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France
2 shared publications Benoîte Lassalle
Centre Louis-Perquin Institut Régional de Réadaptation, Nancy, France
2 shared publications- Claire Charra-Brunaud
Institut de Cancérologie de Lorraine, Department of Radiation Oncology, Vandœuvre-lès-Nancy, France
2 shared publications
Latest Publications
- Open Access
- 3 October 2026
- Published by Springer Nature in BMC Medical Education
Teaching organ-at-risk delineation in the AI era: educational impact and dosimetric relevance of a structured training intervention
- 3 October 2026
- Published by Springer Nature in BMC Medical Education
Open AccessTeaching organ-at-risk delineation in the AI era: educational impact and dosimetric relevance of a structured training intervention
- Open Access
- 10 August 2026
- Published by Springer Nature in Acta Neuropathologica
- Vol. 152 (1)
Cerebrospinal fluid cell-free DNA sequencing in pediatric CNS tumors: towards liquid molecular neuropathology
- 10 August 2026
- Published by Springer Nature in Acta Neuropathologica
- Vol. 152 (1)
Open AccessCerebrospinal fluid cell-free DNA sequencing in pediatric CNS tumors: towards liquid molecular neuropathology
- Open Access
- 28 July 2026
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1)
Operationalizing the EU AI Act in a comprehensive cancer center through an institutional governance framework
The EU AI Act subjects high-risk clinical AI systems to deployer obligations whose institutional operationalization remains undefined. Drawing on experience at a French comprehensive cancer center, we present a governance framework combining three novel components: a dual-axis model for institutional risk stratification, a five-category AI-related adverse event taxonomy inspired by pharmacovigilance, and structured proficiency testing against simulated AI errors. Successful AI integration depends on institutional readiness, not algorithmic performance.
- 28 July 2026
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1)
Open AccessOperationalizing the EU AI Act in a comprehensive cancer center through an institutional governance framework
The EU AI Act subjects high-risk clinical AI systems to deployer obligations whose institutional operationalization remains undefined. Drawing on experience at a French comprehensive cancer center, we present a governance framework combining three novel components: a dual-axis model for institutional risk stratification, a five-category AI-related adverse event taxonomy inspired by pharmacovigilance, and structured proficiency testing against simulated AI errors. Successful AI integration depends on institutional readiness, not algorithmic performance.
- Open Access
- 8 May 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (6) , 522
Sensorineural hearing loss after pediatric cranial radiotherapy: a multicenter analysis of dosimetric and clinical risk factors
Background No multicenter study has validated cochlear dose constraints for hearing preservation in pediatric brain tumor patients in a real-world setting. Although the PENTEC review proposed a 35 Gy mean cochlear dose threshold, supporting evidence from heterogeneous, multicenter pediatric cohorts remains scarce. Purpose To evaluate dosimetric, therapeutic, and clinical risk factors for sensorineural hearing loss (SNHL) after pediatric cranial radiotherapy in a national multicenter cohort, with a specific focus on validating the clinical relevance of the 35 Gy mean cochlear dose threshold. Methods We retrospectively analyzed 88 children treated with cranial radiotherapy between 2014 and 2024 across four French pediatric radiotherapy centers participating in the national PediaRT registry. All patients had baseline and at least two post-radiotherapy audiograms graded according to the Chang Ototoxicity Scale, with SNHL defined as Chang grade ≥ 1a. Mean (Dmean) and minimum (Dmin) cochlear doses were extracted and analyzed using Kaplan–Meier estimates and Cox proportional hazards models. Results Over a median follow-up of 37 months, 17 patients (19.3%) developed SNHL. In multivariate analysis, both a mean cochlear dose ≥ 35 Gy (HR = 3.90; 95% CI: 1.24–12.23; p = 0.020) and cisplatin exposure (HR = 3.85; 95% CI: 1.40–10.64; p = 0.009) were independently associated with SNHL. The 5-year cumulative incidence of SNHL was 43.4% for Dmean ≥ 35 Gy versus 13.1% for < 35 Gy (p = 0.0014), and 51.6% with cisplatin versus 12.4% without (p < 0.001). A significant monotonic relationship between cochlear dose and SNHL severity was observed (p = 0.0011). Conclusion This study provides the first national, multicenter validation of the 35 Gy mean cochlear dose threshold in a real-world pediatric population and identifies cisplatin exposure as a major independent risk factor. These findings support strict cochlear dose minimization during treatment planning and systematic long-term audiological surveillance in pediatric cancer survivorship care.
- 8 May 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (6) , 522
Open AccessSensorineural hearing loss after pediatric cranial radiotherapy: a multicenter analysis of dosimetric and clinical risk factors
Background No multicenter study has validated cochlear dose constraints for hearing preservation in pediatric brain tumor patients in a real-world setting. Although the PENTEC review proposed a 35 Gy mean cochlear dose threshold, supporting evidence from heterogeneous, multicenter pediatric cohorts remains scarce. Purpose To evaluate dosimetric, therapeutic, and clinical risk factors for sensorineural hearing loss (SNHL) after pediatric cranial radiotherapy in a national multicenter cohort, with a specific focus on validating the clinical relevance of the 35 Gy mean cochlear dose threshold. Methods We retrospectively analyzed 88 children treated with cranial radiotherapy between 2014 and 2024 across four French pediatric radiotherapy centers participating in the national PediaRT registry. All patients had baseline and at least two post-radiotherapy audiograms graded according to the Chang Ototoxicity Scale, with SNHL defined as Chang grade ≥ 1a. Mean (Dmean) and minimum (Dmin) cochlear doses were extracted and analyzed using Kaplan–Meier estimates and Cox proportional hazards models. Results Over a median follow-up of 37 months, 17 patients (19.3%) developed SNHL. In multivariate analysis, both a mean cochlear dose ≥ 35 Gy (HR = 3.90; 95% CI: 1.24–12.23; p = 0.020) and cisplatin exposure (HR = 3.85; 95% CI: 1.40–10.64; p = 0.009) were independently associated with SNHL. The 5-year cumulative incidence of SNHL was 43.4% for Dmean ≥ 35 Gy versus 13.1% for < 35 Gy (p = 0.0014), and 51.6% with cisplatin versus 12.4% without (p < 0.001). A significant monotonic relationship between cochlear dose and SNHL severity was observed (p = 0.0011). Conclusion This study provides the first national, multicenter validation of the 35 Gy mean cochlear dose threshold in a real-world pediatric population and identifies cisplatin exposure as a major independent risk factor. These findings support strict cochlear dose minimization during treatment planning and systematic long-term audiological surveillance in pediatric cancer survivorship care.
- Open Access
- 30 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (4)
Beyond Mankind, Self-Illusion and Medical Expertise of Artificial Intelligence in the Era of COVID-19
Arthur Claessens, Yann-Erick Claessens, Aurélien Lambert, William Gehin; Beyond Mankind, Self-Illusion and Medical Expertise of Artificial Intelligence in
- 30 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (4)
Open AccessBeyond Mankind, Self-Illusion and Medical Expertise of Artificial Intelligence in the Era of COVID-19
Arthur Claessens, Yann-Erick Claessens, Aurélien Lambert, William Gehin; Beyond Mankind, Self-Illusion and Medical Expertise of Artificial Intelligence in
- 24 November 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (2) , 102817
Management of radiation-induced gynecological toxicities: AFSOS-SFCE-GFRCP clinical practice guidelines
- 24 November 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (2) , 102817
Management of radiation-induced gynecological toxicities: AFSOS-SFCE-GFRCP clinical practice guidelines
- Open Access
- 15 October 2025
- Published by Elsevier in Brachytherapy
- Vol. 25 (1) , 50-55
Good safety of oblique needle insertion using the Venezia applicator for cervical cancer: A single-center cohort study
- 15 October 2025
- Published by Elsevier in Brachytherapy
- Vol. 25 (1) , 50-55
Open AccessGood safety of oblique needle insertion using the Venezia applicator for cervical cancer: A single-center cohort study
- Open Access
- 25 June 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 195, 110659
AI-based CT assessment of sarcopenia in borderline resectable pancreatic Cancer: A narrative review of clinical and technical perspectives
- 25 June 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 195, 110659
Open AccessAI-based CT assessment of sarcopenia in borderline resectable pancreatic Cancer: A narrative review of clinical and technical perspectives
- Open Access
- 26 May 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 197, 110346
Dosimetric analysis of hearing loss after cranial radiation therapy in children: A single-institution study from the French national registry PediaRT
- 26 May 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 197, 110346
Open AccessDosimetric analysis of hearing loss after cranial radiation therapy in children: A single-institution study from the French national registry PediaRT